Drug
Tirzepatide clinical trials
Also written LY3298176, Mounjaro and Zepbound.
- studies test it
- 180
- open now
- 96
- in phase 3
- 49
- first study started
- 2016
Keep track of what changes. Save the Tirzepatide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
177 studies that test it; most in 2026 (57); 3 more planned to start later
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 12 |
| 2020 | 9 |
| 2021 | 6 |
| 2022 | 5 |
| 2023 | 14 |
| 2024 | 22 |
| 2025 | 45 |
| 2026 | 57 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 6
- Phase 1
- 28
- Phase 2
- 59
- Phase 3
- 49
- Phase 4
- 35
- No phase
- 10
What it is tested for
Each study’s main condition, where its own words name it.
- Obesity
- 63
Who runs them
Industry 85 · Other 95
Eli Lilly and Company (74) · The Cleveland Clinic (4) · University of Texas Southwestern Medical Center (3) · Shahid Beheshti University of Medical Sciences (3) · Mayo Clinic (2) · Novo Nordisk A/S (2) · Zagazig University (2) · University Medical Centre Ljubljana (2)
Often tested with
Tested in the same studies.
Semaglutide (10) · Eloralintide (6) · Bimagrumab (4) · Dulaglutide (3) · Pioglitazone (2) · Bupropion hydrochloride, naltrexone hydrochoride drug combination (1) · Phentermine (1) · Topiramate (1)
Studies
Open first, then newest update. How each study uses Tirzepatide is read from its arms, and is right about nine times in ten.
Testing it · 180
- Tirzepatide Titration to Reduce Side Effects in Individuals With ObesityRecruitingNot applicableDasman Diabetes InstituteNCT07574723Written as Tirzepatide (Per-label titration)
- PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility StudyRecruitingPhase 2M.D. Anderson Cancer CenterNCT07874828Written as Tirzepatide
- A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 DiabetesNot yet recruitingPhase 3Eli Lilly and CompanyNCT07881458Written as eloralintide and tirzepatide
- A Study of EloraTZP in Adult Participants With Obesity Without Type 2 DiabetesNot yet recruitingPhase 3Eli Lilly and CompanyNCT07881432Written as eloralintide and tirzepatide
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide MedicationRecruitingPhase 1Novo Nordisk A/SNCT07868354Written as Tirzepatide
- A Study to Evaluate ALN-2232 in Participants With ObesityRecruitingPhase 1/2Alnylam PharmaceuticalsNCT07463846Written as Tirzepatide
- Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)RecruitingPhase 3Eli Lilly and CompanyNCT07817875Written as Tirzepatide
- Tirzepatide for the Treatment of Cannabis Use DisorderNot yet recruitingPhase 2Brigham and Women's HospitalNCT07265752Written as Tirzepatide
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)RecruitingPhase 3Eli Lilly and CompanyNCT07165028Written as Tirzepatide
- Trial of Innovative Fat-loss Focused Approaches in Patients With Class I Obesity: a Comparative StudyRecruitingNot applicableNational Medical Research Center for Therapy and Preventive MedicineNCT07866183Written as Tirzepatide
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyRecruitingPhase 3Eli Lilly and CompanyNCT06937086Written as Tirzepatide
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightRecruitingPhase 3Eli Lilly and CompanyNCT06937099Written as Tirzepatide
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightRecruitingPhase 2Eli Lilly and CompanyNCT06143956Written as Tirzepatide
- The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With ObesityRecruitingPhase 4Mayo ClinicNCT07218445Written as Tirzepatide
- Tirzepatide in Obesity-Driven Endometrial CancerRecruitingEarly Phase 1UNC Lineberger Comprehensive Cancer CenterNCT07065552Written as Tirzepatide
- Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized TrialNot yet recruitingPhase 2/3yifang zhuNCT07734792Written as Tirzepatide
- Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness TrialNot yet recruitingPhase 2/3Woolcock Institute of Medical ResearchNCT07846865Written as Tirzepatide
- A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDRecruitingPhase 2Regeneron PharmaceuticalsNCT07527910Written as Tirzepatide
- Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial CancerNot yet recruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT07078838Written as Tirzepatide
- Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility StudyRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT06759701Written as Tirzepatide
See all 180 studies that test Tirzepatide →
Given in every arm · 9 — Tirzepatide is usual care beside what is tested
- Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT TrialRecruitingPhase 2City of Hope Medical CenterNCT07202247Written as Tirzepatide
- Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)Not yet recruitingPhase 4University of North Carolina, Chapel HillNCT07756359Written as Tirzepatide
- The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)Not yet recruitingPhase 3University of VirginiaNCT07298915Written as Tirzepatide
- Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without DiabetesActive, not recruitingPhase 1OrsoBio, IncNCT05822544Written as Tirzepatide
- A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With ObesityCompletedPhase 2Eli Lilly and CompanyNCT06373146Written as Tirzepatide
- Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or ObeseCompletedPhase 2Scholar Rock, Inc.NCT06445075Written as Tirzepatide
- A Study of LY3841136 in Overweight and Obese ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06345066Written as Tirzepatide
- A Study of LY3457263 in Obese ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05582096Written as Tirzepatide
- A Study of Tirzepatide Administered by Two Different Devices in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04004988Written as Tirzepatide
As the comparator · 15 — what is tested is compared with Tirzepatide
- A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering MedicationsNot yet recruitingPhase 3Hoffmann-La RocheNCT07889648Written as Tirzepatide
- A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityRecruitingPhase 3PfizerNCT07845500Written as Tirzepatide
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or OverweightRecruitingPhase 1Ascletis Pharma (China) Co., LimitedNCT07842640Written as Tirzepatide
- A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or MetforminNot yet recruitingPhase 2CSPC Ouyi Pharmaceutical Co., Ltd.NCT07796477Written as Tirzepatide Injection 15mg
- AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 DiabetesNot yet recruitingPhase 4The First Affiliated Hospital of Anhui Medical UniversityNCT07697391Written as Tirzepatide
- Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial FibrillationNot yet recruitingNot applicableNational Taiwan University HospitalNCT07382024Written as Tirzepatide
- AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)Not yet recruitingPhase 4Huazhong University of Science and TechnologyNCT07555730Written as Tirzepatide
- Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without DiabetesRecruitingPhase 2Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07521631Written as Tirzepatide
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorCompletedPhase 3Novo Nordisk A/SNCT06221969Written as Tirzepatide
- A Study of BGM0504 in Participants With ObesityCompletedPhase 2BrightGene Bio-Medical Technology Co., Ltd.NCT06911203Written as Tirzepatide
- A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityActive, not recruitingPhase 3Eli Lilly and CompanyNCT06662383Written as Tirzepatide
- Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight ParticipantsCompletedPhase 2Gan and Lee Pharmaceuticals, USANCT06737042Written as Tirzepatide
- A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose WeightCompletedPhase 2Novo Nordisk A/SNCT06326060Written as Tirzepatide
- A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightCompletedPhase 3Novo Nordisk A/SNCT06131437Written as Tirzepatide
- Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityActive, not recruitingPhase 1/2Innovent Biologics (Suzhou) Co. Ltd.NCT07000955Written as Tirzepatide
Codes
What other systems call Tirzepatide · ClinicalTrials.gg INT006887
- MeSH (NLM) D000098860TirzepatideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) OYN3CCI6QETIRZEPATIDEConfirmed FDA, NLM, Wikidata
- RxNorm 2601723One source FDA
- Wikidata Q108324770tirzepatideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174817TirzepatideConfirmed FDA, Wikidata
- DrugBank DB15171One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000098860 | Tirzepatide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | OYN3CCI6QE | TIRZEPATIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2601723 | — | One source FDA |
| Wikidata | Q108324770 | tirzepatide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174817 | Tirzepatide | Confirmed FDA, Wikidata |
| DrugBank | DB15171 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.